GlassScriptPhysician profile
Raquel Ampudia Llano
NPI 1639747140
$4,192.31
in general payments reported to CMS, 2019-2025
23 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $801 · 2023: $1,243 · 2024: $812 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $923.04 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $678.47 | 2022-2025 | |
| Neurelis, INC. | $467.15 | 2022-2025 | Valtoco |
| Ironshore Pharmaceuticals INC. | $381.85 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $307.97 | 2025 | Jornay Pm |
| Corium, LLC | $263.37 | 2022-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $242.18 | 2023-2024 | Aptiom |
| Catalyst Pharmaceuticals, INC. | $207.60 | 2023-2024 | Fycompa |
| Eisai INC. | $191.08 | 2022-2023 | |
| Noven Therapeutics, LLC | $167.31 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $52.07 | 2023 | Elaprase |
| Livanova USA, INC. | $48.87 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $33.96 | 2023-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $32.85 | 2022 | |
| Immedica Pharma US, INC. | $31.20 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $28.76 | 2025 | |
| Acadia Pharmaceuticals INC | $26.78 | 2025 | Daybue |
| Allergan, INC. | $26.15 | 2022 | |
| Aquestive Therapeutics, INC. | $24.15 | 2025 | |
| Neos Therapeutics, LP | $19.55 | 2023 | Adzenys Xr-Odt |
| Sk Life Science, INC. | $13.21 | 2024 | |
| Phadia US INC. | $12.60 | 2022 | |
| Aucta Pharmaceuticals, INC. | $12.14 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Ampudia Llano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.